Gestosis as a course of maternal mortality

Abstract

In the present article analysis of maternal mortality of gestosis is undertaken. The study was carried out from 1996 till 1999 in Saint-Petersburg. During this period nine patients died of gestosis (7.0: 100.000 childbirth). The share of gestosis in the structure of maternal mortality increased from 2 7.9 ±5.7% in 1988- 1995 to 40.9±10.5% in 1996-1999. At the same time the tendency towards increasing of frequency of this complication is displayed: 13.2% in 1986-1990, 24.0% in 1991-1995 and30.5% in 1996-1999. The analysis made it possible to determine two variants of gestosis clinical picture and to expose some mistakes in treatment of patients at the prenatal stage, during the period of delivery and postnatal period.

Keywords

gestosis / maternal mortality / St. Petersburg / incidence / prenatal care / delivery / postpartum period

References

[1] Бровкин Д.П. Профилактика и лечение эклампсии. //Акуш. и гин., 1953, № 3. С. 21 - 26.

[2] Габелова К.А. Роль фиксированных в плаценте иммунных комплексов в патогенезе гестоза. Автореф. канд. дисс., СПб. - 1999.

[3] Зозуля О.В., Рогов В.А., Пятакова Н.В., Тареева И.Е. Оксид азота: роль в развитии осложнений беременности и их профилактике. Терап. архив, 1997. - № 6. С. 17 - 20.

[4] Репина М.А., Корзо Т.М. Нарушения в тромбоцитарном звене гемостаза у беременных с гестозом. Материалы международного семинара “Проблемы беременности высокого риска”, М. - 1999. - С. 88- 90.

[5] Arngrimsson R., Geirsson R. Genetic aspects of Hypertension in Pregnancy. Acta Obst.Gynec. Scand., 1997. - № 167. - P. 18.

[6] Chalkraborty S., Priya К. Treatment of Eclampsia. Acta Obst.Gynec. Scand., 1997-№ 167. - P. 34.

[7] Flock F., Groten T., Fuhrmann R., Kreinberg R. Nitric Oxide Metabolism ex vivo and in vitro in Preeclampsia. Acta Obst.Gynec. Scand., 1997. - № 167. P. 21.

[8] Haig D. Genetic conflicts in human pregnancy. Quart. Rev. Biol., 1993. - Vol. 68., p.495 - 532.

[9] Madazli R., BenianA., Uzun H. et al. Lipid peroxidation and antioxidants in preeclampsia. Eur.Y. Obstet. Gynecol, a Reprod. Biology. - 1999. - Vol. 85/- P. 205 -208.

[10] Margulies M., Voto L. Hypertensive Emergency and Eclampsia. Acta Obst.Gynec. Scand., 1997.- Vol. 76, p. 8.

[11] Naidu S., Moodley J., Gouws E., Mothlhabani B. The efficacy of phenytoin in eclampsia. J. Obst. Gynec., 1997. - Vol. 17, № 1, p. 13-17.

[12] Page E. On the pathogenesis of preeclampsia and eclampsia. J. Obst. Gynec. Brit. Cwth., 1972. - № 10, p. 883 - 894.

[13] Pouta A., Vuolteenaho O., Laatikainen T. Plasma Endothelin in Preeclampsia. Acta Obst.Gynec. Scand., 1997. - Vol. 76, p. 21.

[14] Pritchard J., Cunningham F., Pritchard S. The Parkland memorial hospital protocol for treatment of eclampsia Amer. J. Obst. Gynec., 1984. - №7. - P. 951 - 963.

[15] Qian P, Maltau J., Abyholm T. HELLP-syndrome - a seriös complication of hyprtension in pregnancy. Acta Obst. Gynec. Scand., 1984. - Vol. 63, № 8. p. 727 - 729.

[16] Schwartz M., Brenner W. Toxemia in a patinet with none of the standart signs of preeclampsia. Obst. Gynec., 1984. - № 3. -P. 19-21.

[17] Schuiling G., Koiter T, Faas M. Why preeclampsia? Human Reprod., 1997.- Vol. 12, № 10, p. 2087-2092.

[18] Shamsuddin L., Rouf S., Hussaini A., Khan J. Magnesium sulphate l/s Diazepam in the Management of Eclampsia. Acta Obst.Gynec. Scand., 1997. - № 167, p. 34.

[19] Sud S., Gupta J., Dhaliwal L. et al. Serial plasma fibronectin levels in preeclampsia. Intern. J. Obst. Gynec., 1999. - Vol. 66, p. 123 - 128.

[20] Wang Y., Walsh S. Antioxidant activities and in RNA expression of superoxide dismutase catalase in normal and preeclamptic placentas. J. Soc. Gynecol. Invest., 1996. - № 3, p. 179- 184.

[21] Weinstein L. Syndrome of hemolysis, elevated liver enzymes and low platelet count. Am. J. Obst.Gynec., 1982. - Vol. 142, № 1, p. 159- 165.

RIGHTS & PERMISSIONS

Eсо-Vector